Literature DB >> 33166032

Protective effects of propolis on hepatic steatosis and fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) evaluated by real-time two-dimensional shear wave elastography: A randomized clinical trial.

Davood Soleimani1,2, Mitra Rezaie2, Farnood Rajabzadeh3, Jamshid Gholizadeh Navashenaq4, Mohammadreza Abbaspour5, Mahsa Miryan6, Farkhondeh Razmpour7, Golnaz Ranjbar2, Reza Rezvani2, Lida Jarahi8, Seyed Isaac Hashemy9, Ladan Goshayeshi10, Mohsen Nematy2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, while no drugs have been approved for its treatment. The pieces of evidence indicate that propolis as a novel anti-inflammatory agent might be a promising candidate to treat NAFLD. We aimed to evaluate the efficacy of propolis on hepatic steatosis and fibrosis in patients with NAFLD. This randomized clinical trial was conducted on 54 patients with NAFLD. Patients were randomly assigned to receive propolis tablets at a dose of 250 mg twice daily for 4 months or placebo. The improvement in hepatic steatosis and fibrosis was evaluated using two-dimensional shear wave elastography. Improvement in the hepatic steatosis was significantly higher in the propolis group than the placebo group, even after adjustment for baseline value and changes in weight, energy intake, and physical activity (odds ratio [OR]: 5.67; 95% confidence intervals [CI]: 1.41-22.8; p = .014). A significant reduction was observed on the liver stiffness in the propolis group (-0.65 ± 0.56 kPa; p = .001), whereas it increased in the placebo group (0.27 ± 0.59 kPa; p = .037). Also, the intake of propolis significantly decreased high-sensitivity C-reactive protein (hs-CRP) levels compared with the placebo group (-0.371; 95%CI: -0.582 to -0.16 mg/L; p = .01). Changes in serum levels of fasting blood sugar, alanine aminotransferase, aspartate aminotransferase, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, cholesterol, and triglyceride did not differ significantly between the two groups (p > .05). There was no significant improvement in insulin resistance in both groups (p > .05). Propolis seems to have protective effects on hepatic steatosis and fibrosis and to reduce the serum levels of hs-CRP in patients with NAFLD.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  elastography; fibrosis; liver stiffness; non-alcoholic fatty liver disease; propolis; steatosis

Mesh:

Substances:

Year:  2020        PMID: 33166032     DOI: 10.1002/ptr.6937

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  6 in total

1.  Effects of propolis supplementation on irritable bowel syndrome with constipation (IBS-C) and mixed (IBS-M) stool pattern: A randomized, double-blind clinical trial.

Authors:  Mahsa Miryan; Davood Soleimani; Pejman Alavinejad; Mohammadreza Abbaspour; Alireza Ostadrahimi
Journal:  Food Sci Nutr       Date:  2022-04-20       Impact factor: 3.553

Review 2.  Propolis in Metabolic Syndrome and Its Associated Chronic Diseases: A Narrative Review.

Authors:  Felix Zulhendri; Munir Ravalia; Krishna Kripal; Kavita Chandrasekaran; James Fearnley; Conrad O Perera
Journal:  Antioxidants (Basel)       Date:  2021-02-26

3.  Performance of Imaging Techniques in Non-invasive Diagnosis of Non-alcoholic Fatty Liver Disease in Children: A Systematic Review and Meta-Analysis.

Authors:  Qun Yu; Yiwei Liu; Peipei Hu; Feng Gao; Guoqing Huang
Journal:  Front Pediatr       Date:  2022-07-11       Impact factor: 3.569

4.  Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.

Authors:  Oluyemi Komolafe; Elena Buzzetti; Audrey Linden; Lawrence Mj Best; Angela M Madden; Danielle Roberts; Thomas Jg Chase; Dominic Fritche; Suzanne C Freeman; Nicola J Cooper; Alex J Sutton; Elisabeth Jane Milne; Kathy Wright; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-07-19

5.  Efficacy of Brazilian green propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: A randomized, controlled clinical trial.

Authors:  Marcelo Augusto Duarte Silveira; David De Jong; Andresa Aparecida Berretta; Erica Batista Dos Santos Galvão; Juliana Caldas Ribeiro; Thiago Cerqueira-Silva; Thais Chaves Amorim; Luis Filipe Miranda Rebelo da Conceição; Marcel Miranda Dantas Gomes; Maurício Brito Teixeira; Sergio Pinto de Souza; Marcele Helena Celestino Alves Dos Santos; Raissa Lanna Araújo San Martin; Márcio de Oliveira Silva; Monique Lírio; Lis Moreno; Julio Cezar Miranda Sampaio; Renata Mendonça; Silviana Salles Ultchak; Fabio Santos Amorim; João Gabriel Rosa Ramos; Paulo Benigno Pena Batista; Suzete Nascimento Farias da Guarda; Ana Verena Almeida Mendes; Rogerio da Hora Passos
Journal:  Biomed Pharmacother       Date:  2021-03-20       Impact factor: 6.529

6.  Effect of propolis supplementation on athletic performance, body composition, inflammation, and oxidative stress following intense exercise: A triple-blind randomized clinical trial.

Authors:  Davood Soleimani; Mahsa Miryan; Vahid Hadi; Jamshid Gholizadeh Navashenaq; Jalal Moludi; Sayed Mazaher Sayedi; Mohammad Bagherniya; Gholamreza Askari; Seyyed Mostafa Nachvak; Ehsan Sadeghi; Ali Ashraf Rashidi; Saeid Hadi
Journal:  Food Sci Nutr       Date:  2021-05-08       Impact factor: 2.863

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.